The Successful Use of Meclizine in Panic Disorder
J Clin Psychiatry 2004;65(9):1285-1286 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Sir: A variety of pharmacologic treatments have been recommended in panic disorder, including the selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, benzodiazepines, and monoamine oxidase inhibitors.1 This does not exclude the effectiveness of other medications (e.g., venlafaxine, gabapentin) that may not have been formally studied for the disorder. Meclizine, an H1 receptor antagonist, has not undergone empirical study as a pharmacologic intervention in panic disorder, although Jacob2 indicates its potential effectiveness among individuals with both panic disorder and vestibular symptoms. We present the case of a female patient, seen in a primary care setting, who had been treated with the traditional pharmacotherapies for panic disorder (SSRIs, tricyclic antidepressants, benzodiazepines), but responded well only to meclizine.